title: Dietary polydextrose prevents inflammatory bowel disease in trinitrobenzenesulfonic acid model of rat colitis.
abstract: Inflammatory bowel disease (IBD) is a multifactorial intestinal disorder that involves interactions among the immune system, genetic susceptibility, and environmental factors, especially the bacterial flora. Polydextrose, a polysaccharide constituted by 90% nondigestible and nonabsorbable soluble fibers, has several physiological effects consistent with those of dietary fibers, including proliferation of colon microflora. Because sulfasalazine presents serious side effects through long-term use at high doses, the aim of the present study was to evaluate the preventative effect of polydextrose on trinitrobenzenesulfonic acid-induced intestinal inflammation and its effects on the intestinal anti-inflammatory activity of sulfasalazine. Results indicated that polydextrose and its association with sulfasalazine present an anti-inflammatory effect that reduces myeloperoxidase activity, counteracts glutathione content, and promotes reductions in lesion extension and colonic weight/length ratio.
authors.affiliation: Laboratory of Phytomedicines, Department of Pharmacology, Institute of Biosciences, São Paulo State University-UNESP, Botucatu, São Paulo, Brazil.
authors.forename: Aline
authors.initials: A
authors.lastname: Witaicenis
authors.forename: Andréa C
authors.initials: AC
authors.lastname: Fruet
authors.forename: Letícia
authors.initials: L
authors.lastname: Salem
authors.forename: Luiz C
authors.initials: LC
authors.lastname: Di Stasi
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D003092:Colitis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004347:Drug Interactions; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005936:Glucans / Q000627:therapeutic use*; D005978:Glutathione / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D056692:Prebiotics; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D005936:Glucans; D056692:Prebiotics; D012460:Sulfasalazine; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D000469:Alkaline Phosphatase; D005978:Glutathione; C033375:polydextrose